Literature DB >> 1548092

Protection against lethal pneumococcal septicemia in pigs is associated with decreased levels of interleukin-6 in blood.

H W Ziegler-Heitbrock1, B Passlick, E Käfferlein, P G Coulie, J R Izbicki.   

Abstract

Injection of type 6b pneumococci into pigs results in a sharp rise in levels of interleukin-6 (IL-6) in blood, with an average peak value of 7,700 U/ml at 4 h and mortality in five of seven of these animals. Pretreatment at -24 h with the monocyte activator MTP-PE prevents this strong increase in IL-6 (peak value, 1,000 U/ml) and reduces mortality to zero of six animals. This suggests that MTP-PE, in addition to activating monocytes, protects animals by preventing the harmful increase of cytokines such as IL-6.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548092      PMCID: PMC257049          DOI: 10.1128/iai.60.4.1692-1694.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Molecular mechanisms in down-regulation of tumor necrosis factor expression.

Authors:  J G Haas; P A Baeuerle; G Riethmüller; H W Ziegler-Heitbrock
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Interleukin-6 induction by a muramyltripeptide derivative in cancer patients.

Authors:  H Frost; J L Murray; H A Chaudri; J Van Damme
Journal:  J Biol Response Mod       Date:  1990-04

3.  Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages.

Authors:  J C Mathison; G D Virca; E Wolfson; P S Tobias; K Glaser; R J Ulevitch
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

4.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

Authors:  R C Bone; C J Fisher; T P Clemmer; G J Slotman; C A Metz; R A Balk
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

5.  Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

Authors:  H F Starnes; M K Pearce; A Tewari; J H Yim; J C Zou; J S Abrams
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

6.  Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.

Authors:  A Waage; A Halstensen; T Espevik
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

7.  Differential expression of cytokines in human blood monocyte subpopulations.

Authors:  H W Ziegler-Heitbrock; M Ströbel; D Kieper; G Fingerle; T Schlunck; I Petersmann; J Ellwart; M Blumenstein; J G Haas
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

Review 8.  [Septicemia. Etiology, epidemiology, clinical aspects and prognosis in 446 patients].

Authors:  H Lode; C M Harnoss; B Fangmann; A Loehr; J Wagner
Journal:  Dtsch Med Wochenschr       Date:  1983-12-16       Impact factor: 0.628

9.  Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model.

Authors:  J R Izbicki; C Raedler; A Anke; P Brunner; M Siebeck; E Leinisch; R Lüttiken; G Ruckdeschel; D K Wilker; L Schweiberer
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

Authors:  J Van Snick; S Cayphas; A Vink; C Uyttenhove; P G Coulie; M R Rubira; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more
  8 in total

1.  A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice.

Authors:  K A Benton; M P Everson; D E Briles
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

2.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

3.  Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection.

Authors:  Alison R Kerr; June J Irvine; Jennifer J Search; Neill A Gingles; Aras Kadioglu; Peter W Andrew; William L McPheat; Charles G Booth; Tim J Mitchell
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

4.  Prevention of experimental endotoxin shock by a monocyte activator.

Authors:  B Passlick; M O Labeta; J R Izbicki; P Ostertag; T Löffler; M Siebeck; U Pichlmeier; L Schweiberer; H W Ziegler-Heitbrock
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

5.  Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response.

Authors:  W Chen; E A Havell; F Gigliotti; A G Harmsen
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

6.  Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes.

Authors:  S Houldsworth; P W Andrew; T J Mitchell
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

7.  Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides.

Authors:  P Dieter; U Hempel; S Kamionka; A Kolada; B Malessa; E Fitzke; T A Tran-Thi
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

8.  Analysis of Porcine Pro- and Anti-Inflammatory Cytokine Induction by S. suis In Vivo and In Vitro.

Authors:  Florian S Hohnstein; Marita Meurer; Nicole de Buhr; Maren von Köckritz-Blickwede; Christoph G Baums; Gottfried Alber; Nicole Schütze
Journal:  Pathogens       Date:  2020-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.